Pacira seeks to expand Exparel use in US
This article was originally published in Scrip
Shares of Pacira Pharmaceuticals got a 2.8% boost on 7 May after the company said it was seeking expanded use in the US of its long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) to block nerve pain.
You may also be interested in...
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.